<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neurobiol Aging</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neurobiol. Aging</journal-id>
      <journal-title-group>
        <journal-title>Neurobiology of Aging</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0197-4580</issn>
      <issn pub-type="epub">1558-1497</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23664753</article-id>
      <article-id pub-id-type="pmc">3906605</article-id>
      <article-id pub-id-type="publisher-id">S0197-4580(13)00164-4</article-id>
      <article-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.04.011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Genetic Reports Abstract</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>TDP-43 pathology in a patient carrying G2019S <italic>LRRK2</italic>&#xA0;mutation and a novel p.Q124E <italic>MAPT</italic><sup><xref ref-type="fn" rid="d32e38">&#x2606;</xref></sup></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ling</surname>
            <given-names>Helen</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kara</surname>
            <given-names>Eleanna</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bandopadhyay</surname>
            <given-names>Rina</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hardy</surname>
            <given-names>John</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holton</surname>
            <given-names>Janice</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xiromerisiou</surname>
            <given-names>Georgia</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lees</surname>
            <given-names>Andrew</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houlden</surname>
            <given-names>Henry</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Revesz</surname>
            <given-names>Tamas</given-names>
          </name>
          <email>t.revesz@ucl.ac.uk</email>
          <xref rid="cor1" ref-type="corresp">&#x2217;</xref>
        </contrib>
      </contrib-group>
      <aff>Reta Lila Weston Institute of Neurological Studies and Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>&#x2217;</label>Corresponding author at: Queen Square Brain Bank for Neurological Disorders, 1&#xA0;Wakefield Street, London WC1N 1PJ, UK. Tel.:&#xA0;+44 203 448 4232; fax:&#xA0;+44 203 448&#xA0;4286. <email>t.revesz@ucl.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <volume>34</volume>
      <issue>12</issue>
      <fpage>2889.e5</fpage>
      <lpage>2889.e9</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>2</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>4</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>5</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2013 The Authors</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license xlink:href="https://creativecommons.org/licenses/by/3.0/">
          <license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">CC BY 3.0</ext-link> license</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Leucine-rich repeat kinase 2 (<italic>LRRK2</italic>) mutation is the most common cause of genetic-related parkinsonism and is usually associated with Lewy body pathology; however, tau, &#x3B1;-synuclein, and ubiquitin pathologies have also been reported. We report the case of a patient carrying the <italic>LRRK2</italic> G2019S mutation and a novel heterozygous variant c.370C&gt;G, p.Q124E in exon 4 of the microtubule-associated protein tau (<italic>MAPT</italic>). The patient developed parkinsonism with good levodopa response in her 70s. Neuropathological analysis revealed nigral degeneration and Alzheimer-type tau pathology without Lewy bodies. Immunohistochemical staining using phospho-TDP-43 antibodies identified occasional TDP-43 pathology in the hippocampus, temporal neocortex, striatum, and substantia nigra. However, TDP-43 pathology was not identified in another 4 archival <italic>LRRK2</italic> G2019S cases with Lewy body pathology available in the Queen Square Brain Bank. Among other published cases of patients carrying <italic>LRRK2</italic> G2019S mutation, only 3 were reportedly evaluated for TDP-43 pathology, and the results were negative. The role of the <italic>MAPT</italic> variant in the clinical and pathological manifestation in <italic>LRRK2</italic> cases remains to be determined.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>
          <italic>LRRK2</italic>
        </kwd>
        <kwd>
          <italic>MAPT</italic>
        </kwd>
        <kwd>Parkinson's disease</kwd>
        <kwd>TDP-43</kwd>
        <kwd>tau</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1">
      <label>1</label>
      <title>Introduction</title>
      <p>Among the 5 identified pathogenic leucine-rich repeat kinase 2&#xA0;(<italic>LRRK2</italic>) mutations, G2019S is the most common, and accounts for 1% of sporadic Parkinson's disease and 4% of hereditary parkinsonism worldwide (<xref rid="bib21" ref-type="bibr">Healy et&#xA0;al., 2008</xref>). Clinical presentation of <italic>LRRK2</italic> mutation resembles idiopathic Parkinson's disease but may be associated with a more benign disease course (<xref rid="bib21" ref-type="bibr">Healy et&#xA0;al., 2008</xref>). Most patients with <italic>LRRK2</italic> mutation exhibit neuropathological features consistent with typical Lewy body Parkinson's disease (<xref rid="bib15" ref-type="bibr">Gilks et&#xA0;al., 2005</xref>; <xref rid="bib28" ref-type="bibr">Khan et&#xA0;al., 2005</xref>; <xref rid="bib47" ref-type="bibr">Zimprich et&#xA0;al., 2004</xref>); however, &#x201C;pure&#x201D; nigral degeneration, tau, &#x3B1;-synuclein, or ubiquitin pathologies resembling progressive supranuclear palsy (PSP), multiple system atrophy, and frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) have also been reported (<xref rid="bib8" ref-type="bibr">Dachsel et&#xA0;al., 2007</xref>; <xref rid="bib12" ref-type="bibr">Gaig et&#xA0;al., 2008</xref>; <xref rid="bib14" ref-type="bibr">Giasson et&#xA0;al., 2006</xref>; <xref rid="bib18" ref-type="bibr">Hasegawa et&#xA0;al., 2009</xref>; <xref rid="bib37" ref-type="bibr">Rajput et&#xA0;al., 2006</xref>; <xref rid="bib47" ref-type="bibr">Zimprich et&#xA0;al., 2004</xref>). Ubiquitinated TAR DNA-binding protein&#x2013;43 (TDP-43) is a major disease protein in FTLD and amyotrophic lateral sclerosis (ALS) and can occasionally be observed in Lewy body disorders and tauopathies (<xref rid="bib32" ref-type="bibr">Mackenzie et&#xA0;al., 2010</xref>; <xref rid="bib36" ref-type="bibr">Neumann et&#xA0;al., 2006</xref>; <xref rid="bib40" ref-type="bibr">Sreedharan et&#xA0;al., 2008</xref>). Recently, TDP-43&#x2013;related pathology was reported in 3 patients carrying <italic>LRRK2</italic> mutations (p.R1441C, p.R793M and L1165P) (<xref rid="bib6" ref-type="bibr">Covy et&#xA0;al., 2009</xref>; <xref rid="bib43" ref-type="bibr">Wider et&#xA0;al., 2010</xref>). Here, we report a patient with a clinical diagnosis of Parkinson's disease, who in post-mortem was found to have nigral degeneration without Lewy body pathology, and was&#xA0;also shown to carry the <italic>LRRK2</italic> G2019S mutation and a novel&#xA0;heterozygous variant c.370C&gt;G, p.Q124E in exon 4 of the microtubule-associated protein tau (<italic>MAPT</italic>).</p>
    </sec>
    <sec sec-type="methods" id="sec2">
      <label>2</label>
      <title>Methods</title>
      <sec id="sec2.1">
        <label>2.1</label>
        <title>Case selection and genetic analysis</title>
        <p>Genomic DNA was extracted from frozen brain tissue of these cases, and Sanger sequencing was performed according to standard procedures as previously described (<xref rid="bib27" ref-type="bibr">Kara et&#xA0;al., 2012</xref>). As part of an ongoing clinicopathological study to evaluate archival cases with post-encephalitic parkinsonism (PEP) and unclassifiable tauopathy at the Queen Square Brain Bank for Neurological Disorders (QSBB), we sequenced <italic>LRRK2</italic> (exons 24, 25, 27, 29, 35, 36, 41, and 48), <italic>PARK2</italic> and <italic>MAPT</italic> genes in 13 cases. <italic>PARK2</italic> was chosen because it can cause levodopa-responsive parkinsonism with absence of Lewy bodies (<xref rid="bib11" ref-type="bibr">Doherty et&#xA0;al., 2013</xref>), whereas <italic>LRRK2</italic> mutations are more commonly associated with Lewy body pathology (<xref rid="bib43" ref-type="bibr">Wider et&#xA0;al., 2010</xref>). <italic>MAPT</italic> gene was sequenced because of the presence of tau pathology in these cases. From this cohort, we recently published our findings of the rare <italic>MAPT</italic> p.A152T variant as a risk factor for the development of tauopathies (<xref rid="bib27" ref-type="bibr">Kara et&#xA0;al., 2012</xref>). MRC-Holland (Amsterdam, the Netherlands) multiplex ligation-dependent probe amplification (MLPA) kits (P051, P052) were used for copy-number analysis of the following genes: <italic>PARK2</italic> 6q25.2, <italic>SNCA</italic> 4q21, <italic>Pink1</italic>, <italic>Park7</italic> 1p36, <italic>UCHL1</italic> 4p14, <italic>GCH1</italic> 14q22.1, and <italic>LRRK2</italic> 12q12. Mutations and variants identified in <italic>MAPT, LRRK2,</italic> and <italic>PARK2</italic> were named based on transcripts with accession numbers <ext-link ext-link-type="uri" xlink:href="ncbi-n:NM_005910.5">NM_005910.5</ext-link>/<ext-link ext-link-type="uri" xlink:href="ncbi-p:NP_005901.2">NP_005901.2</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-n:NM_198578.3">NM_198578.3</ext-link>/<ext-link ext-link-type="uri" xlink:href="ncbi-p:NP_940980.3">NP_940980.3</ext-link>, and <ext-link ext-link-type="uri" xlink:href="ncbi-n:NM_004562.2">NM_004562.2</ext-link>/<ext-link ext-link-type="uri" xlink:href="ncbi-p:NP_004553.2">NP_004553.2</ext-link>, respectively. <italic>MAPT</italic> haplotypes were determined by the genotype of the H1/H2-tagging SNP rs1052553 (<xref rid="bib20" ref-type="bibr">Hayesmoore et&#xA0;al., 2009</xref>). The <italic>TDP-43</italic> gene was sequenced in the present case with TDP-43 pathology. In 4 other cases with proven <italic>LRRK2</italic> G2019S mutations and Lewy body pathology available in the QSBB (<xref rid="bib15" ref-type="bibr">Gilks et&#xA0;al., 2005</xref>), sequencing of the <italic>MAPT</italic> gene was performed.</p>
        <p>Subjects in this report had provided written consent to perform neuropathological and genetic studies. All protocols of brain donation had been approved by a London Research Ethics Committee, and tissue is stored for research at the QSBB with a license from the Human Tissue Authority. This research was approved by the Tissue Request Committee of the QSBB.</p>
      </sec>
      <sec id="sec2.2">
        <label>2.2</label>
        <title>Neuropathology</title>
        <p>Following the QSBB protocols, the brains were divided mid-sagittally post mortem. One-half of the brain was immediately frozen and stored at&#xA0;&#x2212;80 &#xB0;C, and the other half was immersed and&#xA0;fixed in 10% neutral formalin for 3 weeks. After slicing and sampling the brain, tissue blocks were processed using standard protocols. We performed hematoxylin and eosin, Luxol fast blue/cresyl violet, and Congo red staining on 7-&#x3BC;m-thick sections, and&#xA0;also used the modified Bielschowsky and Gallyas silver impregnation methods. Immunohistochemistry with antibodies to phospho-tau (AT8 clone recognizing Ser202/Thr205; BioScience Life Sciences; 1:600), 3-repeat (3R) and 4-repeat (4R) tau isoforms (Upstate/Millipore;&#xA0;3R tau: RD3; 1:2000; 4R tau: RD4; 1:200) (<xref rid="bib9" ref-type="bibr">de&#xA0;Silva et&#xA0;al., 2003</xref>), A&#x3B2; (Dako; 6F/3D; 1:100), ubiquitin, p62, TDP, p-TDP, &#x3B1;-synuclein&#xA0;(Vector Laboratories; KM51; 1:50) and phospho-&#x3B1;-synuclein (recognizing Ser 129; Abcam-ab59264; rabbit polyclonal) was carried out using a standard avidin&#x2013;biotin method.</p>
        <p>In 4 other cases with proven <italic>LRRK2</italic> G2019S mutations and Lewy body pathology available in the QSBB (<xref rid="bib15" ref-type="bibr">Gilks et&#xA0;al., 2005</xref>), immunohistochemistry staining using antibody to phospho-TDP-43 (<italic>p</italic>-TDP) was carried out in the hippocampus, amygdala, and upper midbrain blocks.</p>
        <p>To assess whether the neuronal loss in the substantia nigra pars&#xA0;compacta (SNpc) identified in the <italic>LRRK2</italic> case was related to the&#xA0;genetic mutation or to its Alzheimer's related pathology, we performed semi-quantitative assessment of nigral cell loss in 12 randomly selected cases with confirmed pathological diagnosis of Alzheimer's disease (AD).</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3">
      <label>3</label>
      <title>Results</title>
      <sec id="sec3.1">
        <label>3.1</label>
        <title>Genetic analysis</title>
        <p>Of the 13 cases with PEP and unclassifiable tauopathy we identified 1 case with both <italic>LRRK2</italic> G2019S mutation and a heterozygous variant in <italic>MAPT</italic> exon 4 (c.370C&gt;G, p.Q124E) (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>). The <italic>MAPT</italic> p.Q124E variant is absent in all control subjects in the public databases (N&#xA0;= 6568, of which 3913 are caucasians), which&#xA0;include, Ensemble (<ext-link ext-link-type="uri" xlink:href="http://useast.ensembl.org/index.html">http://useast.ensembl.org/index.html</ext-link>) and Exome Variant Server (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>) [(1,2013) accessed]) (see <xref rid="appsec1" ref-type="sec">Supplementary Table&#xA0;1</xref>); this variant is also absent in the 4 <italic>LRRK2</italic> cases with Lewy body pathology. The <italic>MAPT</italic> haplotype of this patient was H1/H2. <italic>PARK2</italic> and <italic>TDP-43</italic> sequencings in this case were negative. A dosage study using MLPA was negative for all analyzed genes including <italic>PARK2</italic> and <italic>LRRK2</italic>.</p>
      </sec>
      <sec id="sec3.2">
        <label>3.2</label>
        <title>Case report</title>
        <p>The British white woman who carried the <italic>LRRK2</italic> G2019S mutation and the heterozygous p.Q124E <italic>MAPT</italic> variant, developed right-hand tremor at age 73 years. She had mild bradykinesia and rigidity and was diagnosed with idiopathic Parkinson's disease. She was initially started on an anticholinergic medication; 5 years later, levodopa therapy was administered and titrated to 1000 mg/day, with a good response. She had no cognitive impairment. Her motor&#xA0;symptoms gradually deteriorated. She reported wearing-off symptoms but never had any dyskinesia. In the last year of life, she had balance difficulty, multiple falls and required a rollator to mobilize. She died at age 85. There was no family history of any movement or neurological disorders.</p>
        <p>Neuropathological analysis confirmed an overall moderate degree of neuronal loss in the SNpc except in the ventrolateral tier,&#xA0;where severe neuronal loss was found (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>). There were no Lewy bodies on &#x3B1;-synuclein or phospho-&#x3B1;-synuclein immunohistochemistry. There were sparse tau-positive neuropil threads (NTs) in the frontal and parietal cortices; sparse NTs, neurofibrillary tangles (NFTs), and pre-tangles (PreTs) in the CA1 and CA4 hippocampal subregions; mild PreTs, moderate numbers of NPs, NFTs and NTs in the subiculum; severe NFTs, NTs, and PreTs in the entorhinal cortex and very sparse NTs in the striatum (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>). All tau inclusions were both 3R- and 4R-tau positive. The subthalamic nucleus was preserved, and no tau pathology was noted.</p>
        <p>A&#x3B2; immunohistochemistry demonstrated parenchymal deposition in the cerebral cortex, hippocampus, and striatum corresponding to Thal phase score of 3 (<xref rid="bib41" ref-type="bibr">Thal et&#xA0;al., 2002</xref>), whereas the distribution of tau pathology corresponded to Braak and Braak stage III (<xref rid="bib3" ref-type="bibr">Braak et&#xA0;al., 2006</xref>). Using the Consortium to Establish a Registry for Alzheimer's disease (CERAD) criteria (<xref rid="bib34" ref-type="bibr">Mirra et&#xA0;al., 1991</xref>), the NP score was &#x201C;sparse&#x201D; in the temporal cortex, &#x201C;moderate&#x201D; in the frontal cortex, and &#x201C;sparse&#x201D; in the parietal cortex. These results gave a &#x201C;low&#x201D; likelihood of AD, according to the National Institute on Ageing (NIA)/Reagan Institute of the Alzheimer Association Consensus Recommendations for the Postmortem Diagnosis of Alzheimer's disease, 1997 (NIA-Reagan criteria) (<xref rid="bib24" ref-type="bibr">Hyman and Trojanowski, 1997</xref>), and &#x201C;intermediate&#x201D; level of AD pathologic change (A2, C2, B2) according to the 2012 guideline (<xref rid="bib23" ref-type="bibr">Hyman et&#xA0;al., 2012</xref>).</p>
        <p>TDP-43 and p-TDP-43 immunohistochemistry showed numerous fine thread-like processes and few coarser neurites in the CA1 hippocampal subregion and subiculum. In the amygdala and the temporal and frontal cortices, there were occasional NCIs and few threads. There were occasional NCIs, threads, and NIIs in the subiculum, striatum, and SN, and skein-like NCIs in the SN (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>).</p>
        <p>There was no hippocampal sclerosis. No &#x3B1;-synuclein immunoreactive inclusions, argyrophilic grains, cerebral amyloid angiopathy (CAA), or vascular pathology was observed. No P62-positve &#x201C;star-shaped&#x201D; inclusion in the hippocampus or small &#x201C;dot-like&#x201D; structures in the cerebellar granule cells were observed.</p>
      </sec>
      <sec id="sec3.3">
        <label>3.3</label>
        <title>Findings in other LRRK2 G2019S cases</title>
        <p>In 4 other cases available in the QSBB with proven <italic>LRRK2</italic> G2019S mutation, no TDP-43&#x2013;related pathology was observed in the hippocampus or amygdala. Sequencing of the <italic>MAPT</italic> gene did not reveal any abnormal finding.</p>
      </sec>
      <sec id="sec3.4">
        <label>3.4</label>
        <title>Nigral degeneration in AD control cases</title>
        <p>In the 12 randomly selected cases with confirmed pathological diagnosis of Alzheimer's disease (NIA/Reagan &#x201C;high&#x201D; likelihood of AD), nigral cell loss was, at most, mild, as evidenced by regional pigment incontinence in the SNpc.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4">
      <label>4</label>
      <title>Discussion</title>
      <p><italic>LRRK2</italic> G2019S mutation is commonly associated with Lewy body pathology. Of the 22 published post-mortem cases with this mutation, only 4 cases had an absence of Lewy bodies. Rajput et&#xA0;al reported a case with slow, progressive, non&#x2013;levodopa-responsive parkinsonism and tau-positive NFTs resembling the neuropathology of PSP (<xref rid="bib37" ref-type="bibr">Rajput et&#xA0;al., 2006</xref>), Giasson et&#xA0;al and Gaig et&#xA0;al each reported a case with classical tremor-dominant parkinsonism and pure nigral degeneration (<xref rid="bib12" ref-type="bibr">Gaig et&#xA0;al., 2008</xref>; <xref rid="bib14" ref-type="bibr">Giasson et&#xA0;al., 2006</xref>), and, Dachsel et&#xA0;al reported a case with dementia and tremor and pathology consisted of FTLD with ubiquitinated neuronal inclusions (FTLD-U) (<xref rid="bib8" ref-type="bibr">Dachsel et&#xA0;al., 2007</xref>). On the other hand, pleomorphic pathologies including &#x3B1;-synuclein, tau, and ubiquitin seem to be more commonly associated with other pathogenic <italic>LRRK2</italic> mutations (<xref rid="bib17" ref-type="bibr">Hasegawa and Kowa, 1997</xref>; <xref rid="bib18" ref-type="bibr">Hasegawa et&#xA0;al., 2009</xref>; <xref rid="bib38" ref-type="bibr">Santpere and Ferrer, 2009</xref>; <xref rid="bib45" ref-type="bibr">Wszolek et&#xA0;al., 1997</xref>, <xref rid="bib44" ref-type="bibr">2004</xref>; <xref rid="bib47" ref-type="bibr">Zimprich et&#xA0;al., 2004</xref>).</p>
      <p>We report a case with <italic>LRRK2</italic> G2019S mutation clinically diagnosed as Parkinson's disease, with good levodopa response, in which neuropathological analysis revealed nigral degeneration with an absence of Lewy bodies, Alzheimer-type tau, and TDP-43 pathologies. Interestingly, this patient was also found to carry a novel p.Q124E <italic>MAPT</italic> variant. Prompted by the TDP-43 pathology, we screened this case for&#xA0;TDP-43 mutations, which were negative. We then surveyed for TDP-43 pathology in another 4 archival QSBB cases with <italic>LRRK2</italic> G2019S mutation and Lewy body pathology, and the findings were negative. These 4 <italic>LRRK2</italic> G2019S cases were also negative for pathogenic mutations or novel variants in <italic>MAPT</italic>. To date, only 3 cases with&#xA0;<italic>LRRK2</italic> mutation have been reported to have TDP-43&#x2013;related pathology (p.R1441C, p.R793M, and L1165P) (<xref rid="bib6" ref-type="bibr">Covy et&#xA0;al., 2009</xref>; <xref rid="bib47" ref-type="bibr">Zimprich et&#xA0;al., 2004</xref>), none of which had the G2019S mutation. Only 3&#xA0;other published cases carrying the <italic>LRRK2</italic> G2019S mutation were&#xA0;evaluated for TDP-43 pathology (<xref rid="bib14" ref-type="bibr">Giasson et&#xA0;al., 2006</xref>) but no TDP-43&#x2013;positive inclusions were observed (<xref rid="bib6" ref-type="bibr">Covy et&#xA0;al., 2009</xref>).</p>
      <p>The discovery of TDP-43 in 2006 as a major disease protein in FTLD and ALS led to the introduction of TDP-43 immunohistochemistry into the routine diagnostic protocols of brain banks in the&#xA0;last few years. It is therefore likely that other reported <italic>LRRK2</italic> cases with ubiquitin pathology may also have TDP-43 inclusions and will warrant comprehensive assessment (<xref rid="bib8" ref-type="bibr">Dachsel et&#xA0;al., 2007</xref>; <xref rid="bib45" ref-type="bibr">Wszolek et&#xA0;al., 1997</xref>, <xref rid="bib44" ref-type="bibr">2004</xref>; <xref rid="bib47" ref-type="bibr">Zimprich et&#xA0;al., 2004</xref>). In addition to FTLD-TDP and ALS, TDP-43 inclusions can sometimes be detected in other neurodegenerative diseases including AD, Lewy body disorders, and primary tauopathies including corticobasal degeneration, PSP, parkinsonism-dementia complex of Guam, and dementia pugilistica (<xref rid="bib2" ref-type="bibr">Arai et&#xA0;al., 2009</xref>; <xref rid="bib19" ref-type="bibr">Hasegawa et&#xA0;al., 2007</xref>; <xref rid="bib30" ref-type="bibr">King et&#xA0;al., 2010</xref>; <xref rid="bib32" ref-type="bibr">Mackenzie et&#xA0;al., 2010</xref>; <xref rid="bib33" ref-type="bibr">McKee et&#xA0;al., 2013</xref>; <xref rid="bib42" ref-type="bibr">Uryu et&#xA0;al., 2008</xref>; <xref rid="bib48" ref-type="bibr">Yokota et al., 2010</xref>). The cause and mechanism of TDP-43 in tauopathies are not known, but it has been postulated that tau aggregates may promote aggregation of TDP-43 through cross-seeding (<xref rid="bib35" ref-type="bibr">Morales et&#xA0;al., 2009</xref>; <xref rid="bib42" ref-type="bibr">Uryu et&#xA0;al., 2008</xref>). TDP-43 immunoreactivity may modify clinical features in AD and other types of dementia (<xref rid="bib26" ref-type="bibr">Josephs et&#xA0;al., 2008</xref>; <xref rid="bib31" ref-type="bibr">Lashley et&#xA0;al., 2011</xref>), and is also closely associated with hippocampal sclerosis (<xref rid="bib1" ref-type="bibr">Amador-Ortiz et&#xA0;al., 2007</xref>; <xref rid="bib26" ref-type="bibr">Josephs et&#xA0;al., 2008</xref>). It remains to be determined whether TDP-43 protein plays a role in influencing the clinical features in <italic>LRRK2</italic> cases. As in Lewy-body Parkinson's disease, nigral degeneration is a typical finding in <italic>LRRK2</italic> mutation and is considered to be the pathological substrate of clinical parkinsonism in these patients (<xref rid="bib43" ref-type="bibr">Wider et&#xA0;al., 2010</xref>). Although previous studies have shown a correlation between nigral pathology and extrapyramidal symptoms in AD (<xref rid="bib4" ref-type="bibr">Burns et&#xA0;al., 2005</xref>), our screening of 12 randomly selected AD cases did not reveal significant nigral cell loss, in contrast to the present <italic>LRRK2</italic> case. It is therefore unlikely that the modest Alzheimer-type tau pathology in this case would explain the extent of the nigral cell loss.</p>
      <p>The pleomorphic pathologies in <italic>LRRK2</italic> mutation supports the&#xA0;notion that <italic>LRRK2</italic> acts upstream from the pathway of other proteins implicated in neuronal death; and it is likely that genetic&#xA0;and environmental factors then influence the type of proteinopathy that eventually develops in the individual, whether it is &#x3B1;-synuclein,&#xA0;tau, or ubiquitin pathology (<xref rid="bib43" ref-type="bibr">Wider et&#xA0;al., 2010</xref>). The novel <italic>MAPT</italic> variant identified in our case is located in a region of the protein far from microtubule-binding domains and does not have an obvious role in the molecule's function. A similar variant was also recently reported in exon 7 of the <italic>MAPT</italic> gene (<xref rid="bib5" ref-type="bibr">Coppola et&#xA0;al., 2012</xref>; <xref rid="bib7" ref-type="bibr">Cruchaga et&#xA0;al., 2012</xref>; <xref rid="bib25" ref-type="bibr">Jin et&#xA0;al., 2012</xref>; <xref rid="bib27" ref-type="bibr">Kara et&#xA0;al., 2012</xref>), and a rare variant p.A239T in exon 8 (<ext-link ext-link-type="uri" xlink:href="ncbi-n:NM_005910.5">NM_005910.5</ext-link>) was found in a carrier of a C9orf72 repeat expansion (<xref rid="bib29" ref-type="bibr">King et&#xA0;al., 2013</xref>) (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>). Interestingly, these 3 rare variants all localize in an uncharacterized region of the <italic>MAPT</italic> protein in cases with unexpected tau pathology, which supports the speculation that these variants may have a disease-modifying role and may predispose the individual to tau pathology (<xref rid="bib5" ref-type="bibr">Coppola et&#xA0;al., 2012</xref>; <xref rid="bib10" ref-type="bibr">Devine and Lewis, 2008</xref>; <xref rid="bib13" ref-type="bibr">Gan-Or et&#xA0;al., 2012</xref>; <xref rid="bib27" ref-type="bibr">Kara et&#xA0;al., 2012</xref>). However, the precise mechanism of this relation is far from clear, and our genetic findings in this case serve as an interesting observation rather than yielding a definitive conclusion. It is noteworthy that, in <italic>LRRK2</italic> cases with atypical clinical presentation and/or unusual pathologies, one should also consider the possibility of a coincidental neurodegenerative process with a non-penetrant <italic>LRRK2</italic> mutation (<xref rid="bib16" ref-type="bibr">Goldwurm et&#xA0;al., 2011</xref>; <xref rid="bib39" ref-type="bibr">Sierra et&#xA0;al., 2011</xref>; <xref rid="bib46" ref-type="bibr">Xiromerisiou et&#xA0;al., 2012</xref>).</p>
    </sec>
    <sec id="sec5">
      <title>Disclosure statement</title>
      <p>None of the authors have potential or actual conflicts of interest, and all the authors have seen the manuscript before submission. The work was funded by the Reta Lila Weston Foundation and the PSP Brain Bank. The funding source had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There is no animal work in this study, and the human work on blood and pathology materials has been carried out in compliance with UK regulations.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Amador-Ortiz</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Personett</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Duara</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Graff-Radford</surname>
              <given-names>N.R.</given-names>
            </name>
            <name>
              <surname>Hutton</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease</article-title>
          <source>Ann. Neurol.</source>
          <volume>61</volume>
          <year>2007</year>
          <fpage>435</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="pmid">17469117</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Arai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>I.R.</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nonoka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Niizato</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tsuchiya</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Iritani</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Onaya</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies</article-title>
          <source>Acta Neuropathol.</source>
          <volume>117</volume>
          <year>2009</year>
          <fpage>125</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="pmid">19139911</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Braak</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Alafuzoff</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Arzberger</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kretzschmar</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Del Tredici</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry</article-title>
          <source>Acta Neuropathol.</source>
          <volume>112</volume>
          <year>2006</year>
          <fpage>389</fpage>
          <lpage>404</lpage>
          <pub-id pub-id-type="pmid">16906426</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Burns</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Galvin</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Roe</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>McKeel</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs</article-title>
          <source>Neurology</source>
          <volume>64</volume>
          <year>2005</year>
          <fpage>1397</fpage>
          <lpage>1403</lpage>
          <pub-id pub-id-type="pmid">15851730</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Coppola</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Chinnathambi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Dombroski</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Soto-Ortolaza</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>A.Y.</given-names>
            </name>
            <name>
              <surname>Sears</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Karydas</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Kenet</surname>
              <given-names>R.O.</given-names>
            </name>
            <name>
              <surname>Biernat</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Cotman</surname>
              <given-names>C.W.</given-names>
            </name>
            <name>
              <surname>Decarli</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Levey</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Ringman</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Chui</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Le Ber</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Brice</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lupton</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Preza</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Lovestone</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Graff-Radford</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>B.F.</given-names>
            </name>
            <name>
              <surname>Lippa</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Bigio</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Finger</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kertesz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Caselli</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Gearing</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Juncos</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Ghetti</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Spina</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bordelon</surname>
              <given-names>Y.M.</given-names>
            </name>
            <name>
              <surname>Tourtellotte</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Frosch</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Vonsattel</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Zarow</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Beach</surname>
              <given-names>T.G.</given-names>
            </name>
            <name>
              <surname>Albin</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J.Q.</given-names>
            </name>
            <name>
              <surname>Van Deerlin</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Galasko</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Masliah</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Troncoso</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Hannequin</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Boxer</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Geschwind</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mandelkow</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
            <name>
              <surname>Uitti</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Haines</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Mayeux</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Pericak-Vance</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Rademakers</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Schellenberg</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Mandelkow</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Geschwind</surname>
              <given-names>D.H.</given-names>
            </name>
          </person-group>
          <article-title>Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases</article-title>
          <source>Hum. Mol. Genet.</source>
          <volume>21</volume>
          <year>2012</year>
          <fpage>3500</fpage>
          <lpage>3512</lpage>
          <pub-id pub-id-type="pmid">22556362</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Covy</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Hurtig</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>Van Deerlin</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Giasson</surname>
              <given-names>B.I.</given-names>
            </name>
          </person-group>
          <article-title>Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations</article-title>
          <source>Move. Disord.</source>
          <volume>24</volume>
          <year>2009</year>
          <fpage>32</fpage>
          <lpage>39</lpage>
        </element-citation>
      </ref>
      <ref id="bib7">
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Cruchaga</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Haller</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Chakraverty</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mayo</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Vallania</surname>
              <given-names>F.L.</given-names>
            </name>
            <name>
              <surname>Mitra</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Faber</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Diaz-Arrastia</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Foroud</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>B.F.</given-names>
            </name>
            <name>
              <surname>Graff-Radford</surname>
              <given-names>N.R.</given-names>
            </name>
            <name>
              <surname>St Jean</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ehm</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Mayeux</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Goate</surname>
              <given-names>A.M.</given-names>
            </name>
            <collab>Consortium, N.-L.N.F.S</collab>
          </person-group>
          <article-title>Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families</article-title>
          <source>PLoS One</source>
          <volume>7</volume>
          <year>2012</year>
          <fpage>e31039</fpage>
          <pub-id pub-id-type="pmid">22312439</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Dachsel</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Mata</surname>
              <given-names>I.F.</given-names>
            </name>
            <name>
              <surname>Kachergus</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Toft</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Adamson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hutton</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions</article-title>
          <source>Acta Neuropathol.</source>
          <volume>113</volume>
          <year>2007</year>
          <fpage>601</fpage>
          <lpage>606</lpage>
          <pub-id pub-id-type="pmid">17151837</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>de Silva</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lashley</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gibb</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hanger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hope</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bandopadhyay</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Utton</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Strand</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jowett</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Anderton</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies</article-title>
          <source>Neuropathol. Appl. Neurobiol.</source>
          <volume>29</volume>
          <year>2003</year>
          <fpage>288</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">12787326</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Devine</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2</article-title>
          <source>FEBS J.</source>
          <volume>275</volume>
          <year>2008</year>
          <fpage>5748</fpage>
          <lpage>5757</lpage>
          <pub-id pub-id-type="pmid">19021752</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Doherty</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Silveira-Moriyama</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Parkkinen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Farrell</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mencacci</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Brett</surname>
              <given-names>F.M.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Counihan</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>Z.V.</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Parkin disease: a clinicopathologic entity?</article-title>
          <source>JAMA Neurol.</source>
          <volume>70</volume>
          <year>2013</year>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="bib12">
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Gaig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ezquerra</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Marti</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Valldeoriola</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Llado</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rey</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Cardozo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Molinuevo</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Tolosa</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration</article-title>
          <source>J.&#xA0;Neurol. Sci.</source>
          <volume>270</volume>
          <year>2008</year>
          <fpage>94</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">18353371</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Gan-Or</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bar-Shira</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mirelman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gurevich</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Giladi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Orr-Urtreger</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction</article-title>
          <source>J.&#xA0;Mol. Neurosci.</source>
          <volume>46</volume>
          <year>2012</year>
          <fpage>541</fpage>
          <lpage>544</lpage>
          <pub-id pub-id-type="pmid">21898123</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Giasson</surname>
              <given-names>B.I.</given-names>
            </name>
            <name>
              <surname>Covy</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Bonini</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Hurtig</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J.Q.</given-names>
            </name>
            <name>
              <surname>Van Deerlin</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Biochemical and pathological characterization of Lrrk2</article-title>
          <source>Ann. Neurol.</source>
          <volume>59</volume>
          <year>2006</year>
          <fpage>315</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="pmid">16437584</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Gilks</surname>
              <given-names>W.P.</given-names>
            </name>
            <name>
              <surname>Abou-Sleiman</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Singleton</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Bhatia</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Bonifati</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>N.P.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>N.W.</given-names>
            </name>
          </person-group>
          <article-title>A&#xA0;common LRRK2 mutation in idiopathic Parkinson's disease</article-title>
          <source>Lancet</source>
          <volume>365</volume>
          <year>2005</year>
          <fpage>415</fpage>
          <lpage>416</lpage>
          <pub-id pub-id-type="pmid">15680457</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Goldwurm</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tunesi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tesei</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sironi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Primignani</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Pezzoli</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease</article-title>
          <source>Move. Disord.</source>
          <volume>26</volume>
          <year>2011</year>
          <fpage>2144</fpage>
          <lpage>2145</lpage>
        </element-citation>
      </ref>
      <ref id="bib17">
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Hasegawa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kowa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy</article-title>
          <source>Eur. Neurol.</source>
          <volume>38</volume>
          <issue>suppl 1</issue>
          <year>1997</year>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">9276200</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Hasegawa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Stoessl</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kowa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
            <name>
              <surname>Yagishita</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes</article-title>
          <source>Parkinsonism Relat. Disord.</source>
          <volume>15</volume>
          <year>2009</year>
          <fpage>300</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">18804399</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Hasegawa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Arai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nonaka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oyanagi</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>TDP-43 is deposited in the Guam parkinsonism-dementia complex brains</article-title>
          <source>Brain</source>
          <volume>130</volume>
          <year>2007</year>
          <fpage>1386</fpage>
          <lpage>1394</lpage>
          <pub-id pub-id-type="pmid">17439983</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Hayesmoore</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Bray</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Cross</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>O'Donovan</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>H.R.</given-names>
            </name>
          </person-group>
          <article-title>The effect of age and the H1c MAPT haplotype on MAPT expression in human brain</article-title>
          <source>Neurobiol. Aging</source>
          <volume>30</volume>
          <year>2009</year>
          <fpage>1652</fpage>
          <lpage>1656</lpage>
          <pub-id pub-id-type="pmid">18276036</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Healy</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Falchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>O'Sullivan</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Bonifati</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Durr</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bressman</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brice</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Aasly</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zabetian</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Goldwurm</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Tolosa</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kay</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Marras</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
            <name>
              <surname>Berciano</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Schapira</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bhatia</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Gasser</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>N.W.</given-names>
            </name>
          </person-group>
          <article-title>Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study</article-title>
          <source>Lancet Neurol.</source>
          <volume>7</volume>
          <year>2008</year>
          <fpage>583</fpage>
          <lpage>590</lpage>
          <pub-id pub-id-type="pmid">18539534</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Hyman</surname>
              <given-names>B.T.</given-names>
            </name>
            <name>
              <surname>Phelps</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Beach</surname>
              <given-names>T.G.</given-names>
            </name>
            <name>
              <surname>Bigio</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Cairns</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Carrillo</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Duyckaerts</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Frosch</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Masliah</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mirra</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>P.T.</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Thal</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Thies</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J.Q.</given-names>
            </name>
            <name>
              <surname>Vinters</surname>
              <given-names>H.V.</given-names>
            </name>
            <name>
              <surname>Montine</surname>
              <given-names>T.J.</given-names>
            </name>
          </person-group>
          <article-title>National Institute on Aging&#x2013;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease</article-title>
          <source>Alzheimers Dement.</source>
          <volume>8</volume>
          <year>2012</year>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">22265587</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>Hyman</surname>
              <given-names>B.T.</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J.Q.</given-names>
            </name>
          </person-group>
          <article-title>Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease</article-title>
          <source>J.&#xA0;Neuropathol. Exp. Neurol.</source>
          <volume>56</volume>
          <year>1997</year>
          <fpage>1095</fpage>
          <lpage>1097</lpage>
          <pub-id pub-id-type="pmid">9329452</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Jin</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Pastor</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cervantes</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Benitez</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Razquin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Goate</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cruchaga</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort</article-title>
          <source>Alzheimers Res. Ther.</source>
          <volume>4</volume>
          <year>2012</year>
          <fpage>34</fpage>
          <pub-id pub-id-type="pmid">22906081</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>Josephs</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Whitwell</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Knopman</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>W.T.</given-names>
            </name>
            <name>
              <surname>Stroh</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rademakers</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Boeve</surname>
              <given-names>B.F.</given-names>
            </name>
            <name>
              <surname>Parisi</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>G.E.</given-names>
            </name>
            <name>
              <surname>Ivnik</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Jack</surname>
              <given-names>C.R.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype</article-title>
          <source>Neurology</source>
          <volume>70</volume>
          <year>2008</year>
          <fpage>1850</fpage>
          <lpage>1857</lpage>
          <pub-id pub-id-type="pmid">18401022</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Kara</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Pittman</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>de Silva</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Simone</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Rohrer</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Xiromerisiou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Houlden</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features</article-title>
          <source>Neurobiol. Aging</source>
          <volume>33</volume>
          <year>2012</year>
          <fpage>2231.e7</fpage>
          <lpage>2231.e14</lpage>
          <pub-id pub-id-type="pmid">22595371</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>N.L.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Pavese</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Abou-Sleiman</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Gilks</surname>
              <given-names>W.P.</given-names>
            </name>
            <name>
              <surname>Sweeney</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Ganguly</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Eunson</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Katzenschlager</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gayton</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lennox</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nicholl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bhatia</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Piccini</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Singleton</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>N.W.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data</article-title>
          <source>Brain</source>
          <volume>128</volume>
          <year>2005</year>
          <fpage>2786</fpage>
          <lpage>2796</lpage>
          <pub-id pub-id-type="pmid">16272164</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Al-Sarraj</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Troakes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>B.N.</given-names>
            </name>
            <name>
              <surname>Maekawa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Iovino</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Spillantini</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant</article-title>
          <source>Acta Neuropathol.</source>
          <volume>125</volume>
          <year>2013</year>
          <fpage>303</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="pmid">23053136</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <element-citation publication-type="journal" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sweeney</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bodi</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Troakes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Maekawa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Al-Sarraj</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease</article-title>
          <source>Neuropathology</source>
          <volume>30</volume>
          <year>2010</year>
          <fpage>408</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">20102526</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Lashley</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>TDP-43 pathology may occur in the BRI2 gene-related dementias</article-title>
          <source>Acta Neuropathol.</source>
          <volume>121</volume>
          <year>2011</year>
          <fpage>559</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="pmid">21340582</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Mackenzie</surname>
              <given-names>I.R.</given-names>
            </name>
            <name>
              <surname>Rademakers</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia</article-title>
          <source>Lancet Neurol.</source>
          <volume>9</volume>
          <year>2010</year>
          <fpage>995</fpage>
          <lpage>1007</lpage>
          <pub-id pub-id-type="pmid">20864052</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>McKee</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Nowinski</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Daneshvar</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>V.E.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Wojtowicz</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Baugh</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>D.O.</given-names>
            </name>
            <name>
              <surname>Kubilus</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Cormier</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Ikezu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Reichard</surname>
              <given-names>R.R.</given-names>
            </name>
            <name>
              <surname>Wolozin</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Budson</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>L.E.</given-names>
            </name>
            <name>
              <surname>Kowall</surname>
              <given-names>N.W.</given-names>
            </name>
            <name>
              <surname>Cantu</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>The&#xA0;spectrum of disease in chronic traumatic encephalopathy</article-title>
          <source>Brain</source>
          <volume>136</volume>
          <year>2013</year>
          <fpage>43</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">23208308</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>Mirra</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Heyman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>McKeel</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sumi</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Crain</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Brownlee</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>F.S.</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>van Belle</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease</article-title>
          <source>Neurology</source>
          <volume>41</volume>
          <year>1991</year>
          <fpage>479</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="pmid">2011243</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>Morales</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Soto</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Cross currents in protein misfolding disorders: interactions and therapy</article-title>
          <source>CNS Neurol. Disord. Drug Targets</source>
          <volume>8</volume>
          <year>2009</year>
          <fpage>363</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">19702573</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Neumann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sampathu</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Truax</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Micsenyi</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>Bruce</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Schuck</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>McCluskey</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Masliah</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>I.R.</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Feiden</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Kretzschmar</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J.Q.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title>
          <source>Science</source>
          <volume>314</volume>
          <year>2006</year>
          <fpage>130</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="pmid">17023659</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <element-citation publication-type="journal" id="sref37">
          <person-group person-group-type="author">
            <name>
              <surname>Rajput</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Dachsel</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Lincoln</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Cobb</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Rajput</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Parkinsonism, Lrrk2 G2019S, and tau neuropathology</article-title>
          <source>Neurology</source>
          <volume>67</volume>
          <year>2006</year>
          <fpage>1506</fpage>
          <lpage>1508</lpage>
          <pub-id pub-id-type="pmid">17060589</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <element-citation publication-type="journal" id="sref38">
          <person-group person-group-type="author">
            <name>
              <surname>Santpere</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ferrer</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>LRRK2 and neurodegeneration</article-title>
          <source>Acta Neuropathol.</source>
          <volume>117</volume>
          <year>2009</year>
          <fpage>227</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="pmid">19142648</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <element-citation publication-type="journal" id="sref39">
          <person-group person-group-type="author">
            <name>
              <surname>Sierra</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gonzalez-Aramburu</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Sanchez-Juan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sanchez-Quintana</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Polo</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Berciano</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Combarros</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Infante</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain)</article-title>
          <source>Move. Disord.</source>
          <volume>26</volume>
          <year>2011</year>
          <fpage>2343</fpage>
          <lpage>2346</lpage>
        </element-citation>
      </ref>
      <ref id="bib40">
        <element-citation publication-type="journal" id="sref40">
          <person-group person-group-type="author">
            <name>
              <surname>Sreedharan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Blair</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Tripathi</surname>
              <given-names>V.B.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rogelj</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Ackerley</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Durnall</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Buratti</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Baralle</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>de Belleroche</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Leigh</surname>
              <given-names>P.N.</given-names>
            </name>
            <name>
              <surname>Al-Chalabi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis</article-title>
          <source>Science</source>
          <volume>319</volume>
          <year>2008</year>
          <fpage>1668</fpage>
          <lpage>1672</lpage>
          <pub-id pub-id-type="pmid">18309045</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <element-citation publication-type="journal" id="sref41">
          <person-group person-group-type="author">
            <name>
              <surname>Thal</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Rub</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Orantes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Braak</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Phases of A beta-deposition in the human brain and its relevance for the development of AD</article-title>
          <source>Neurology</source>
          <volume>58</volume>
          <year>2002</year>
          <fpage>1791</fpage>
          <lpage>1800</lpage>
          <pub-id pub-id-type="pmid">12084879</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <element-citation publication-type="journal" id="sref42">
          <person-group person-group-type="author">
            <name>
              <surname>Uryu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nakashima-Yasuda</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Forman</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Kretzschmar</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J.Q.</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies</article-title>
          <source>J.&#xA0;Neuropathol. Exp. Neurol.</source>
          <volume>67</volume>
          <year>2008</year>
          <fpage>555</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="pmid">18520774</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <element-citation publication-type="journal" id="sref43">
          <person-group person-group-type="author">
            <name>
              <surname>Wider</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
          </person-group>
          <article-title>Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation</article-title>
          <source>Neurodegener. Dis.</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>175</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="pmid">20197701</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <element-citation publication-type="journal" id="sref44">
          <person-group person-group-type="author">
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
            <name>
              <surname>Pfeiffer</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Tsuboi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Uitti</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>McComb</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Stoessl</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Strongosky</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Zimprich</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Muller-Myhsok</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Gasser</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Calne</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Autosomal dominant parkinsonism associated with variable synuclein and tau pathology</article-title>
          <source>Neurology</source>
          <volume>62</volume>
          <year>2004</year>
          <fpage>1619</fpage>
          <lpage>1622</lpage>
          <pub-id pub-id-type="pmid">15136696</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <element-citation publication-type="journal" id="sref45">
          <person-group person-group-type="author">
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
            <name>
              <surname>Vieregge</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Uitti</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Gasser</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yasuhara</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>McGeer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Calne</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Vingerhoets</surname>
              <given-names>F.J.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Pfeiffer</surname>
              <given-names>R.F.</given-names>
            </name>
          </person-group>
          <article-title>German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia&#x2014;longitudinal observations</article-title>
          <source>Parkinsonism Relat. Disord.</source>
          <volume>3</volume>
          <year>1997</year>
          <fpage>125</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="pmid">18591067</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <element-citation publication-type="journal" id="sref46">
          <person-group person-group-type="author">
            <name>
              <surname>Xiromerisiou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Houlden</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sailer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Silveira-Moriyama</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease</article-title>
          <source>Move. Disord.</source>
          <volume>27</volume>
          <year>2012</year>
          <fpage>1323</fpage>
        </element-citation>
      </ref>
      <ref id="bib48">
        <element-citation publication-type="journal" id="sref48">
          <person-group person-group-type="author">
            <name>
              <surname>Yokota</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Bigio</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Ishizu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Terada</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Arai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sikkink</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pickering-Brown</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy</article-title>
          <source>Acta neuropathologica</source>
          <volume>120</volume>
          <year>2010</year>
          <fpage>55</fpage>
          <lpage>66</lpage>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00401-010-0702-1">http://dx.doi.org/10.1007/s00401-010-0702-1</ext-link>
          </comment>
          <pub-id pub-id-type="pmid">20512649</pub-id>
        </element-citation>
      </ref>
      <ref id="bib47">
        <element-citation publication-type="journal" id="sref47">
          <person-group person-group-type="author">
            <name>
              <surname>Zimprich</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Biskup</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Leitner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lichtner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lincoln</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kachergus</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hulihan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Uitti</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Calne</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Stoessl</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Pfeiffer</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Patenge</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Carbajal</surname>
              <given-names>I.C.</given-names>
            </name>
            <name>
              <surname>Vieregge</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Asmus</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Muller-Myhsok</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Meitinger</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Strom</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Wszolek</surname>
              <given-names>Z.K.</given-names>
            </name>
            <name>
              <surname>Gasser</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</article-title>
          <source>Neuron</source>
          <volume>44</volume>
          <year>2004</year>
          <fpage>601</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="pmid">15541309</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="appsec1" sec-type="supplementary-material">
      <label>Appendix A</label>
      <title>Supplementary data</title>
      <p>
        <supplementary-material content-type="local-data" id="ec1">
          <caption>
            <p>Supplementary table&#xA0;1</p>
          </caption>
          <media xlink:href="mmc1.docx"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>H.L. is supported by the <funding-source id="gs2">PSP (Europe) Association Research Fellowship Grant</funding-source> [6AMN].</p>
      <p>The authors thank Mark Gaskin and Jamie Toombs for sample organization and preparation of human tissue, Linda Parsons for extracting tissue samples, Robert Courtney for immunohistochemistry staining, Tammaryn Lashley for providing control cases, and Aoife Kiely for provision of the phospho-&#x3B1;-synuclein antibody.</p>
      <p>The authors also thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926), and the Heart GO Sequencing Project (HL-103010). The authors thank the NIEHS Environmental Genome Project for providing support for this project under contract no.HHSN273200800010C.</p>
      <p>This work was supported in part by the <funding-source id="gs3">Wellcome Trust/MRC Joint Call in Neurodegeneration</funding-source> award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC), whose members are from the UCL Institute of Neurology, the University of Sheffield and the MRC Protein Phosphorylation Unit at the University of Dundee. The research was partly supported by the <funding-source id="gs4">National Institute for Health Research</funding-source> (NIHR) Biomedical Research Unit in Dementia based at University College London Hospitals (UCLH), <funding-source id="gs5">University College London</funding-source> (UCL). The views expressed are those of the author(s) and not&#xA0;necessarily those of the NHS, the NIHR, or the Department of Health.</p>
    </ack>
    <fn-group>
      <fn id="d32e38">
        <label>&#x2606;</label>
        <p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
      </fn>
      <fn id="appsec2" fn-type="supplementary-material">
        <label>Appendix A</label>
        <p>Supplementary data associated with this article can be found, in&#xA0;the online version, at <ext-link ext-link-type="doi" xlink:href="10.1016/j.neurobiolaging.2013.04.011">http://dx.doi.org/10.1016/j.neurobiolaging.2013.04.011</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Fig.&#xA0;1</label>
      <caption>
        <p>Diagram of the <italic>MAPT</italic> gene depicting the location of the 3 rare variants reported to date to be associated with tau pathology. The novel variant c.370C&gt;G is indicated with a black arrow on the chromatogram above the p.Q124E variant.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Fig.&#xA0;2</label>
      <caption>
        <p>Key neuropathological findings in the present case. Severe loss of neuromelanin-containing neurons in the ventrolateral tier of the substantia nigra (arrows), as well as gliosis and free pigment (arrowheads) (A); Abundant tau-positive neurofibrillary tangles, neuropil threads, and pre-tangles in the entorhinal cortex (B); phospho-TDP-43 (<italic>p</italic>-TDP) immunoreactive neuronal cytoplasmic inclusions (NCIs), neurites, and a skein-like structure (inset) in the substantia nigra (C); and numerous <italic>p</italic>-TDP&#x2013;positive fine thread-like processes, few coarser neurites, round, dot-like structures, and a &#x201C;cat's-eye&#x201D; neuronal intranuclear inclusion (NII) (inset) in the subiculum (D). A, hematoxylin and eosin staining; B, AT8; and C and D, phospho-TDP-43 immunostaining.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
